AR090590A1 - COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA - Google Patents
COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASAInfo
- Publication number
- AR090590A1 AR090590A1 ARP130101086A ARP130101086A AR090590A1 AR 090590 A1 AR090590 A1 AR 090590A1 AR P130101086 A ARP130101086 A AR P130101086A AR P130101086 A ARP130101086 A AR P130101086A AR 090590 A1 AR090590 A1 AR 090590A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compounds
- alkyl
- amino
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se divulgan compuestos inhibidores de b-Lactamasa (BLI), incluyendo a compuestos que tienen actividad contra b-lactamasas de clase A, clase C o clase D. También se divulgan métodos para fabricar los BLI, y usos de los compuestos en la preparación de composiciones farmacéuticas y aplicaciones antibacteriales. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde X se selecciona entre O y S; R se selecciona entre los restos del grupo de fórmulas (2); R¹ se selecciona entre: a) hidrógeno; b) un compuesto de fórmula (3), donde R² se selecciona entre los restos del grupo de fórmulas (4), donde cada uno de R³, R⁴ y R⁵ se selecciona en forma independiente entre hidrógeno, alquilo C₁₋₃, aminoalquilo, aminocicloalquilo, y hidroxialquilo, y n se selecciona entre 1, 2 y 3; c) el compuesto de fórmula (5), donde R⁶ es H, alquil C₂₋₃amino, y un resto de fórmula (6); d) amino; e) el resto de fórmula (7), donde R⁷ se selecciona entre H, alquilo C₁₋₃ no sustituido, amino-alquilo C₂₋₃, aminocicloalquilo, hidroxialquilo, y el resto de fórmula (6) y donde cada uno de p y q se selecciona en forma independiente entre 1 y 2; y f) -CH(R⁸)CH₂NH₂ donde R⁸ se selecciona entre amino e hidroxilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261618131P | 2012-03-30 | 2012-03-30 | |
US201361790579P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090590A1 true AR090590A1 (es) | 2014-11-26 |
Family
ID=49261280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101086A AR090590A1 (es) | 2012-03-30 | 2013-04-03 | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA |
Country Status (16)
Country | Link |
---|---|
US (7) | US8933232B2 (es) |
EP (1) | EP2831075B1 (es) |
JP (1) | JP2015514095A (es) |
KR (1) | KR20140144254A (es) |
CN (1) | CN104334558A (es) |
AR (1) | AR090590A1 (es) |
AU (1) | AU2013237939A1 (es) |
CA (1) | CA2868553A1 (es) |
CO (1) | CO7091178A2 (es) |
IL (1) | IL234842A0 (es) |
MX (1) | MX2014011827A (es) |
PH (1) | PH12014502196A1 (es) |
RU (1) | RU2014143821A (es) |
SG (1) | SG11201406123TA (es) |
TW (1) | TW201343645A (es) |
WO (1) | WO2013149121A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
SG11201406120SA (en) * | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
US8933232B2 (en) * | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
AU2013268415B2 (en) * | 2012-05-30 | 2017-05-25 | Meiji Seika Pharma Co., Ltd. | Novel beta-lactamase inhibitor and method for producing same |
US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
US9006421B2 (en) | 2013-03-14 | 2015-04-14 | Cubist Pharmaceuticals, Inc. | Cephalosporin compositions and methods of manufacture |
WO2014152996A1 (en) * | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
KR20160108409A (ko) | 2014-01-21 | 2016-09-19 | 욱크하르트 리미티드 | 질소 내포 화합물 및 항세균제로서 이들의 용도 |
AU2015236369B2 (en) | 2014-03-24 | 2017-02-16 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
WO2015150891A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester |
IN2014MU01196A (es) * | 2014-03-29 | 2015-10-02 | Wockhardt Ltd | |
BR112016024235A2 (pt) * | 2014-04-18 | 2017-08-15 | Wockhardt Ltd | composições farmacêuticas compreendendo agentes antibacterianos |
WO2015159263A1 (en) * | 2014-04-18 | 2015-10-22 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015173663A1 (en) * | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester |
WO2015173665A1 (en) * | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate |
MX2017006383A (es) | 2014-11-17 | 2017-08-21 | Entasis Therapeutics Ltd | Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes. |
WO2016118565A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
WO2016157057A1 (en) * | 2015-03-27 | 2016-10-06 | Wockhardt Limited | A process for preparation of sodium salt of (2s, 5r) sulfuric acid mono-(2-[1,3,4]oxadiazol-2-yl-7-oxo-1,6-diazabicyclo[3.2.1 ]oct-6-yl)ester |
MX2017014080A (es) * | 2015-05-07 | 2018-07-06 | Mutabilis | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. |
EP3356357A4 (en) | 2015-10-02 | 2019-02-20 | LegoChem Biosciences, Inc. | COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE |
WO2017203266A1 (en) | 2016-05-25 | 2017-11-30 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
LT3512851T (lt) | 2016-09-16 | 2022-10-25 | Entasis Therapeutics Limited | Beta-laktamazės inhibitorių junginiai |
JOP20190061A1 (ar) | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
US10404592B2 (en) * | 2017-03-24 | 2019-09-03 | Cisco Technology, Inc. | System and method to facilitate content forwarding using bit index explicit replication (BIER) in an information-centric networking (ICN) environment |
WO2018193369A1 (en) * | 2017-04-18 | 2018-10-25 | Wockhardt Limited | Antibacterial compositions |
DK3630111T3 (en) | 2017-05-08 | 2022-03-14 | Entasis Therapeutics Inc | Compounds and methods for treating bacterial infections |
ES2928152T3 (es) | 2017-12-01 | 2022-11-15 | Qilu Pharmaceutical Co Ltd | Forma cristalina de un inhibidor de beta-lactamasa y método de preparación de la misma |
EP3744722A4 (en) * | 2018-01-25 | 2021-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Ss-LACTAMASE INHIBITOR AND ITS USE |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
CA3113606A1 (en) * | 2018-09-21 | 2020-03-26 | Api Corporation | Method for producing amino acid derivatives |
CN111777607A (zh) * | 2020-07-21 | 2020-10-16 | 海南海灵化学制药有限公司 | 一种阿维巴坦纳的制备方法 |
CN116514696B (zh) * | 2023-06-29 | 2023-12-01 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
EP0087953B1 (en) | 1982-02-27 | 1988-04-27 | Beecham Group Plc | Antibacterial 1-normon-2-yl-heterocyclic compounds |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
WO1995005384A1 (en) | 1993-08-13 | 1995-02-23 | Smithkline Beecham Plc | Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity |
AU764348B2 (en) | 1998-09-25 | 2003-08-14 | Cubist Pharmaceuticals Llc | Methods for administration of antibiotics |
US20130059774A1 (en) | 2000-08-01 | 2013-03-07 | Mahesh Vithalbhai Patel | Efflux pump inhibitors |
WO2011101710A1 (en) | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Efflux pump inhibitors |
FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
JP2007533740A (ja) | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Bace阻害剤としてのアミド |
WO2006125974A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
EP2015755A4 (en) | 2006-04-28 | 2010-02-24 | Wockhardt Ltd | ENHANCED TREATMENT FOR TREATING BACTERIAL RESISTANT INFECTIONS |
WO2008039420A2 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
TW200930707A (en) * | 2007-11-13 | 2009-07-16 | Protez Pharmaceuticals Inc | Beta-lactamase inhibitors |
RU2445314C9 (ru) * | 2008-01-18 | 2013-04-10 | Мерк Шарп Энд Домэ Корп. | Ингибиторы бета-лактамаз |
FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
WO2010118361A1 (en) * | 2009-04-09 | 2010-10-14 | Sopharmia, Inc. | Beta lactamase inhibitors |
US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
US8630784B2 (en) | 2010-07-19 | 2014-01-14 | Honda Motor Co., Ltd. | Method and system for detecting and compensating weather condition effects on wireless signals |
US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
CA2822758C (en) | 2010-12-22 | 2018-03-20 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivative and process for preparing the same |
US8829191B2 (en) | 2011-06-17 | 2014-09-09 | Melanie Simone Ronsheim | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
WO2013014496A1 (en) | 2011-07-26 | 2013-01-31 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
KR101738210B1 (ko) | 2011-07-26 | 2017-05-19 | 욱크하르트 리미티드 | 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물 |
CN103649088B (zh) | 2011-08-30 | 2016-05-11 | 沃克哈特有限公司 | 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途 |
WO2013038330A1 (en) | 2011-09-13 | 2013-03-21 | Wockhardt Limited | Nitrogen containing compounds and their use |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
US8933232B2 (en) * | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
SG11201406120SA (en) * | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
AU2013268415B2 (en) | 2012-05-30 | 2017-05-25 | Meiji Seika Pharma Co., Ltd. | Novel beta-lactamase inhibitor and method for producing same |
WO2014152996A1 (en) * | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
-
2013
- 2013-03-29 US US13/853,439 patent/US8933232B2/en active Active
- 2013-03-29 EP EP13769724.9A patent/EP2831075B1/en active Active
- 2013-03-29 JP JP2015503631A patent/JP2015514095A/ja active Pending
- 2013-03-29 US US13/853,443 patent/US8933233B2/en active Active
- 2013-03-29 US US13/853,460 patent/US8962844B2/en active Active
- 2013-03-29 SG SG11201406123TA patent/SG11201406123TA/en unknown
- 2013-03-29 RU RU2014143821A patent/RU2014143821A/ru unknown
- 2013-03-29 WO PCT/US2013/034562 patent/WO2013149121A1/en active Application Filing
- 2013-03-29 US US13/853,452 patent/US8940897B2/en active Active
- 2013-03-29 TW TW102111614A patent/TW201343645A/zh unknown
- 2013-03-29 CN CN201380028018.6A patent/CN104334558A/zh active Pending
- 2013-03-29 KR KR1020147030475A patent/KR20140144254A/ko not_active Application Discontinuation
- 2013-03-29 AU AU2013237939A patent/AU2013237939A1/en not_active Abandoned
- 2013-03-29 MX MX2014011827A patent/MX2014011827A/es unknown
- 2013-03-29 US US13/853,327 patent/US8962843B2/en active Active
- 2013-03-29 CA CA2868553A patent/CA2868553A1/en not_active Abandoned
- 2013-04-03 AR ARP130101086A patent/AR090590A1/es unknown
-
2014
- 2014-09-28 IL IL234842A patent/IL234842A0/en unknown
- 2014-09-30 CO CO14216414A patent/CO7091178A2/es unknown
- 2014-09-30 PH PH12014502196A patent/PH12014502196A1/en unknown
- 2014-10-02 US US14/505,445 patent/US20150031665A1/en not_active Abandoned
- 2014-10-02 US US14/505,442 patent/US20150031659A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8962844B2 (en) | 2015-02-24 |
PH12014502196A1 (en) | 2014-12-10 |
EP2831075B1 (en) | 2017-11-08 |
AU2013237939A1 (en) | 2014-10-30 |
US20130296293A1 (en) | 2013-11-07 |
CA2868553A1 (en) | 2013-10-03 |
US8940897B2 (en) | 2015-01-27 |
US8962843B2 (en) | 2015-02-24 |
US20130303504A1 (en) | 2013-11-14 |
US20150031665A1 (en) | 2015-01-29 |
CN104334558A (zh) | 2015-02-04 |
US20150031659A1 (en) | 2015-01-29 |
SG11201406123TA (en) | 2014-10-30 |
RU2014143821A (ru) | 2016-05-27 |
EP2831075A1 (en) | 2015-02-04 |
IL234842A0 (en) | 2014-12-31 |
JP2015514095A (ja) | 2015-05-18 |
WO2013149121A8 (en) | 2014-05-01 |
EP2831075A4 (en) | 2015-09-09 |
CO7091178A2 (es) | 2014-10-21 |
WO2013149121A1 (en) | 2013-10-03 |
US20130296290A1 (en) | 2013-11-07 |
TW201343645A (zh) | 2013-11-01 |
KR20140144254A (ko) | 2014-12-18 |
US8933232B2 (en) | 2015-01-13 |
US20130296291A1 (en) | 2013-11-07 |
US20130296292A1 (en) | 2013-11-07 |
US8933233B2 (en) | 2015-01-13 |
MX2014011827A (es) | 2015-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
UY32660A (es) | Derivados aminobutricos sustituidos como inhibidores de neprilisina | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
AR106252A2 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
UY32978A (es) | Derivados de la cromenona | |
AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
AR090474A1 (es) | Compuestos de tetrahidropirrolotiazina | |
AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
AR090806A1 (es) | Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii | |
UY35209A (es) | Compuestos tricíclicos | |
AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
BR112014006643A2 (pt) | compostos de imidazopiridina, composições e métodos de uso dos mesmos | |
CU20190042A7 (es) | Compuestos derivados de naftiridinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |